Long-term safety data are of particular interest following the results of the ORAL Surveillance study, which showed that, in patients with RA aged 50 years or older with at least one additional cardiovascular risk factor, the incidence of major cardiovascular events and cancer was higher in those treated with tofacitinib than in those treated with a TNF inhibitor.17 Here, TNF is linked to rheumatoid arthritis.